Avanos Medical (AVNS) Liabilities and Shareholders Equity (2013 - 2026)

Avanos Medical has reported Liabilities and Shareholders Equity for 14 years, with the latest figure at $1.1 billion in Q1 2026.

• Quarterly Liabilities and Shareholders Equity fell 5.21% year-over-year to $1.1 billion in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $4.2 billion (down 24.13% YoY) and the FY2025 annual result came in at $1.1 billion, down 6.97% from the prior year.
• Liabilities and Shareholders Equity fell to $1.1 billion in Q1 2026 per AVNS's latest filing, from $1.1 billion in the prior quarter.
• Over five years, Liabilities and Shareholders Equity peaked at $1.8 billion in Q4 2022 and troughed at $1.0 billion in Q2 2025.
• A 5-year average of $1.5 billion and a median of $1.7 billion in 2024 frame the typical range for Liabilities and Shareholders Equity.
• The sharpest annual moves came in 2022 and 2025: Liabilities and Shareholders Equity gained 11.43% in 2022, then plunged 37.33% in 2025.
• Over 5 years, Liabilities and Shareholders Equity stood at $1.8 billion in 2022, then fell by 5.29% to $1.7 billion in 2023, then slumped by 31.8% to $1.2 billion in 2024, then slipped by 6.97% to $1.1 billion in 2025, then fell by 2.2% to $1.1 billion in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $1.1 billion, $1.1 billion, and $1.1 billion for Q1 2026, Q4 2025, and Q3 2025 respectively.